AGER and neoplasm: TFPI2 induces inflammatory mediators like high mobility group box 1 (HMGB1), which interacts with toll like receptor 4 (TLR4) and receptor for advanced glycation end products (RAGE), establishing a feedback loop that amplifies NF-κB activation, promoting inflammation and tumor progression (Figure 2(3)) [55].